Proteomics

Dataset Information

0

Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer


ABSTRACT: Cervical cancer is one of the leading causes of cancer related deaths among females. Due to proper screening programmes, most of the cervical cancer cases are presented in the locally advanced stage of the disease. Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer. However, resistance to CCRT limit the success of the treatment regimen. In this study, we investigated the altered phosphoproteome of CCRT resistant and sensitive cohort using Mass spectrometry-based proteomics. We carried out phosphoproteomic analysis of treatment naïve cervical cancer patients whose response to CCRT is recorded. The Phosphoproteomic analysis revealed kinases and the pathways associated with CCRT resistance in cervical cancer patients.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cervical Carcinoma Cell, Epithelial Cell

DISEASE(S): Cervix Carcinoma

SUBMITTER: Irene A George  

LAB HEAD: Prashant Kumar

PROVIDER: PXD055164 | Pride | 2024-12-12

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Cervical_10_R1.raw Raw
Cervical_10_R2.raw Raw
Cervical_11_R1.raw Raw
Cervical_11_R2.raw Raw
Cervical_1_R1.raw Raw
Items per page:
1 - 5 of 25

Similar Datasets

2014-05-01 | E-GEOD-56303 | biostudies-arrayexpress
2021-06-04 | GSE145037 | GEO
2014-05-01 | GSE56303 | GEO
2018-03-12 | PXD008436 | Pride
2022-11-22 | GSE218181 | GEO
2023-03-11 | PXD023302 | Pride
| PRJNA705749 | ENA
2020-02-22 | GSE145666 | GEO
2011-02-10 | GSE20298 | GEO
2007-07-31 | GSE8604 | GEO